# Boston Biomedical Innovation Center

> **NIH NIH U54** · BRIGHAM AND WOMEN'S HOSPITAL · 2021 · $1,243,351

## Abstract

A well-recognized gap exists in the path from biomedical discovery in academia to clinical application and 
commercialization of therapeutic, device, and diagnostic technologies in cardiovascular, pulmonary, 
hematologic, and sleep disorders. This chasm is the result of inadequate funding for support of proof-of-concept 
or validation studies essential for early stage development; insufficient access to the resources and 
expertise needed to develop new technologies; and a lack of knowledge and experience among academic 
investigators in bringing new ideas to commercial realization. Within the partnering institutions included in 
this application, the essential elements exist with which to build the infrastructure needed to support and 
sustain the uninterrupted, durable flow of inventions from discovery through development and 
commercialization. While these institutions have a clear track record of remarkably successful development 
of many biomedical technologies, most of these commercial successes have been achieved by the tenacity 
of individual inventors rather than with the help of committed institutional mechanisms. We proposed to 
address these key shortcomings by establishing the regional Boston Center for Accelerated Innovation in 
Therapeutics, Devices, and Diagnostics for Heart, Lung, Blood, and Sleep Disorders (B-BIC, or the Boston 
Biomedical Innovation Center). The key objectives of this Center are to: 1) develop an integrated 
infrastructure that would expand the universe of commercializable technologies for heart, lung, blood, and 
sleep disorders; 2) place these opportunities in the proper evaluative context through an engagement ("seed 
it"), solicitation ("find it"), and selection ("pick it") strategy; 3) efficiently and effectively bring those selected to 
an appropriate exit point from the development process; and 4) provide the educational and mentoring 
infrastructure necessary for the development of the proper entrepreneurial skills among academic 
innovators. By achieving these goals, B-BlC would change the culture of our academic environment, as 
well as the relationship between the public and private sectors in facilitating successful development 
strategies for technologies in heart, lung, blood, and sleep disorders for the ultimate benefit of patients and society.

## Key facts

- **NIH application ID:** 10316833
- **Project number:** 4U54HL119145-08
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** DAVID E. GOLAN
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,243,351
- **Award type:** 4N
- **Project period:** 2020-12-21 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10316833

## Citation

> US National Institutes of Health, RePORTER application 10316833, Boston Biomedical Innovation Center (4U54HL119145-08). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10316833. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*